NCT00526721

Brief Summary

To evaluate achievement ratio of treatment target goal in hypercholesterolemia patients with high risk after high dose rosuvastatin(20mg/day) titration

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
1,482

participants targeted

Target at P75+ for all trials

Timeline
Completed

Started May 2007

Shorter than P25 for all trials

Geographic Reach
1 country

3 active sites

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

May 1, 2007

Completed
4 months until next milestone

First Submitted

Initial submission to the registry

September 5, 2007

Completed
5 days until next milestone

First Posted

Study publicly available on registry

September 10, 2007

Completed
7 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

April 1, 2008

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

April 1, 2008

Completed
Last Updated

March 20, 2012

Status Verified

March 1, 2012

Enrollment Period

11 months

First QC Date

September 5, 2007

Last Update Submit

March 19, 2012

Conditions

Hypercholesterolemia

Keywords

HypercholesterolemiaCrestorLDL target goalhigh risk patientsNaturalisticObservational

Eligibility Criteria

Age18 Years+
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)
Sampling MethodProbability Sample
Study Population

Hypercholesteromia patients with high risk according to NCEP ATP III guideline in Korean tertiary care centers

You may qualify if:

  • High-risk hyperlipidemia patients who are prescribed with rosuvastatin 10mg, based on the physician's clinical decision and fulfill the following criteria
  • Over 18 years of age
  • Have history of CHD or CHD risk equivalents, such as peripheral arterial disease, abdominal aortic aneurysm, symptomatic carotid artery disease (TIA or stroke of carotid origin or \>50% obstruction of carotid artery), DM, and 2+ risk factors with 10-year risk CHD\>20%

You may not qualify if:

  • Patients already taking other hyperlipidemic agents
  • Patients who do not fulfil the indication criteria for statin therapy
  • Patients who do not have baseline and/or follow-up lipid data to verify the efficacy data

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (3)

Research Site

Seoul, Jongro-gu, South Korea

Location

Research Site

Seoul, Kangnam-gu, South Korea

Location

Research Site

Seoul, Songpa-gu, South Korea

Location

MeSH Terms

Conditions

Hypercholesterolemia

Condition Hierarchy (Ancestors)

HyperlipidemiasDyslipidemiasLipid Metabolism DisordersMetabolic DiseasesNutritional and Metabolic Diseases

Study Officials

  • Hyunah Caroline Choi

    AstraZeneca Korea

    STUDY DIRECTOR

Study Design

Study Type
observational
Observational Model
CASE CONTROL
Time Perspective
PROSPECTIVE
Sponsor Type
INDUSTRY
Responsible Party
SPONSOR

Study Record Dates

First Submitted

September 5, 2007

First Posted

September 10, 2007

Study Start

May 1, 2007

Primary Completion

April 1, 2008

Study Completion

April 1, 2008

Last Updated

March 20, 2012

Record last verified: 2012-03

Locations

KR(3)